118 related articles for article (PubMed ID: 37074069)
1. MYC Induces Immunotherapy and IFNγ Resistance Through Downregulation of JAK2.
Markovits E; Harush O; Baruch EN; Shulman ED; Debby A; Itzhaki O; Anafi L; Danilevsky A; Shomron N; Ben-Betzalel G; Asher N; Shapira-Frommer R; Schachter J; Barshack I; Geiger T; Elkon R; Besser MJ; Markel G
Cancer Immunol Res; 2023 Jul; 11(7):909-924. PubMed ID: 37074069
[TBL] [Abstract][Full Text] [Related]
2. Tumor CDKN2A-Associated JAK2 Loss and Susceptibility to Immunotherapy Resistance.
Horn S; Leonardelli S; Sucker A; Schadendorf D; Griewank KG; Paschen A
J Natl Cancer Inst; 2018 Jun; 110(6):677-681. PubMed ID: 29917141
[TBL] [Abstract][Full Text] [Related]
3. Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions.
Sucker A; Zhao F; Pieper N; Heeke C; Maltaner R; Stadtler N; Real B; Bielefeld N; Howe S; Weide B; Gutzmer R; Utikal J; Loquai C; Gogas H; Klein-Hitpass L; Zeschnigk M; Westendorf AM; Trilling M; Horn S; Schilling B; Schadendorf D; Griewank KG; Paschen A
Nat Commun; 2017 May; 8():15440. PubMed ID: 28561041
[TBL] [Abstract][Full Text] [Related]
4. JAK2, PD-L1, and PD-L2 (9p24.1) amplification in metastatic mucosal and cutaneous melanomas with durable response to immunotherapy.
Gupta S; Vanderbilt CM; Cotzia P; Arias Stella JA; Chang JC; Chen Y; Tang LH; DeLair DF; Yao J; Ladanyi M; Ross DS
Hum Pathol; 2019 Jun; 88():87-91. PubMed ID: 30236595
[TBL] [Abstract][Full Text] [Related]
5. Intratumoral interferon-gamma increases chemokine production but fails to increase T cell infiltration of human melanoma metastases.
Mauldin IS; Wages NA; Stowman AM; Wang E; Smolkin ME; Olson WC; Deacon DH; Smith KT; Galeassi NV; Chianese-Bullock KA; Dengel LT; Marincola FM; Petroni GR; Mullins DW; Slingluff CL
Cancer Immunol Immunother; 2016 Oct; 65(10):1189-99. PubMed ID: 27522581
[TBL] [Abstract][Full Text] [Related]
6. Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.
Zaretsky JM; Garcia-Diaz A; Shin DS; Escuin-Ordinas H; Hugo W; Hu-Lieskovan S; Torrejon DY; Abril-Rodriguez G; Sandoval S; Barthly L; Saco J; Homet Moreno B; Mezzadra R; Chmielowski B; Ruchalski K; Shintaku IP; Sanchez PJ; Puig-Saus C; Cherry G; Seja E; Kong X; Pang J; Berent-Maoz B; Comin-Anduix B; Graeber TG; Tumeh PC; Schumacher TN; Lo RS; Ribas A
N Engl J Med; 2016 Sep; 375(9):819-29. PubMed ID: 27433843
[TBL] [Abstract][Full Text] [Related]
7. Tumor Interferon Signaling Is Regulated by a lncRNA INCR1 Transcribed from the PD-L1 Locus.
Mineo M; Lyons SM; Zdioruk M; von Spreckelsen N; Ferrer-Luna R; Ito H; Alayo QA; Kharel P; Giantini Larsen A; Fan WY; Auduong S; Grauwet K; Passaro C; Khalsa JK; Shah K; Reardon DA; Ligon KL; Beroukhim R; Nakashima H; Ivanov P; Anderson PJ; Lawler SE; Chiocca EA
Mol Cell; 2020 Jun; 78(6):1207-1223.e8. PubMed ID: 32504554
[TBL] [Abstract][Full Text] [Related]
8. MYC activation impairs cell-intrinsic IFNγ signaling and confers resistance to anti-PD1/PD-L1 therapy in lung cancer.
Alburquerque-Bejar JJ; Navajas-Chocarro P; Saigi M; Ferrero-Andres A; Morillas JM; Vilarrubi A; Gomez A; Mate JL; Munoz-Marmol AM; Romero OA; Blecua P; Davalos V; Esteller M; Pros E; Llabata P; Torres-Diz M; Esteve-Codina A; Sanchez-Cespedes M
Cell Rep Med; 2023 Apr; 4(4):101006. PubMed ID: 37044092
[TBL] [Abstract][Full Text] [Related]
9. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice.
Liu C; Peng W; Xu C; Lou Y; Zhang M; Wargo JA; Chen JQ; Li HS; Watowich SS; Yang Y; Tompers Frederick D; Cooper ZA; Mbofung RM; Whittington M; Flaherty KT; Woodman SE; Davies MA; Radvanyi LG; Overwijk WW; Lizée G; Hwu P
Clin Cancer Res; 2013 Jan; 19(2):393-403. PubMed ID: 23204132
[TBL] [Abstract][Full Text] [Related]
10. Tumor-Specific Effector CD8+ T Cells That Can Establish Immunological Memory in Humans after Adoptive Transfer Are Marked by Expression of IL7 Receptor and c-myc.
Chandran SS; Paria BC; Srivastava AK; Rothermel LD; Stephens DJ; Kammula US
Cancer Res; 2015 Aug; 75(16):3216-26. PubMed ID: 26100671
[TBL] [Abstract][Full Text] [Related]
11. IFNγ induces PD-L1 overexpression by JAK2/STAT1/IRF-1 signaling in EBV-positive gastric carcinoma.
Moon JW; Kong SK; Kim BS; Kim HJ; Lim H; Noh K; Kim Y; Choi JW; Lee JH; Kim YS
Sci Rep; 2017 Dec; 7(1):17810. PubMed ID: 29259270
[TBL] [Abstract][Full Text] [Related]
12. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
[TBL] [Abstract][Full Text] [Related]
13. IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression.
Thiem A; Hesbacher S; Kneitz H; di Primio T; Heppt MV; Hermanns HM; Goebeler M; Meierjohann S; Houben R; Schrama D
J Exp Clin Cancer Res; 2019 Sep; 38(1):397. PubMed ID: 31506076
[TBL] [Abstract][Full Text] [Related]
14. A secondary role for hypoxia and HIF1 in the regulation of (IFNγ-induced) PD-L1 expression in melanoma.
van Duijn A; Willemsen KJ; van Uden NOP; Hoyng L; Erades S; Koster J; Luiten RM; Bakker WJ
Cancer Immunol Immunother; 2022 Mar; 71(3):529-540. PubMed ID: 34268602
[TBL] [Abstract][Full Text] [Related]
15. Association of IFN-gamma signal transduction defects with impaired HLA class I antigen processing in melanoma cell lines.
Respa A; Bukur J; Ferrone S; Pawelec G; Zhao Y; Wang E; Marincola FM; Seliger B
Clin Cancer Res; 2011 May; 17(9):2668-78. PubMed ID: 21248298
[TBL] [Abstract][Full Text] [Related]
16. Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma.
Yu J; Yan J; Guo Q; Chi Z; Tang B; Zheng B; Yu J; Yin T; Cheng Z; Wu X; Yu H; Dai J; Sheng X; Si L; Cui C; Bai X; Mao L; Lian B; Wang X; Yan X; Li S; Zhou L; Flaherty KT; Guo J; Kong Y
Clin Cancer Res; 2019 Nov; 25(21):6511-6523. PubMed ID: 31375512
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive analysis of tumor necrosis factor receptor TNFRSF9 (4-1BB) DNA methylation with regard to molecular and clinicopathological features, immune infiltrates, and response prediction to immunotherapy in melanoma.
Fröhlich A; Loick S; Bawden EG; Fietz S; Dietrich J; Diekmann E; Saavedra G; Fröhlich H; Niebel D; Sirokay J; Zarbl R; Gielen GH; Kristiansen G; Bootz F; Landsberg J; Dietrich D
EBioMedicine; 2020 Feb; 52():102647. PubMed ID: 32028068
[TBL] [Abstract][Full Text] [Related]
18. Multiple structural and epigenetic defects in the human leukocyte antigen class I antigen presentation pathway in a recurrent metastatic melanoma following immunotherapy.
Chang CC; Pirozzi G; Wen SH; Chung IH; Chiu BL; Errico S; Luongo M; Lombardi ML; Ferrone S
J Biol Chem; 2015 Oct; 290(44):26562-75. PubMed ID: 26381407
[TBL] [Abstract][Full Text] [Related]
19.
Saigi M; Alburquerque-Bejar JJ; Mc Leer-Florin A; Pereira C; Pros E; Romero OA; Baixeras N; Esteve-Codina A; Nadal E; Brambilla E; Sanchez-Cespedes M
Clin Cancer Res; 2018 Sep; 24(18):4579-4587. PubMed ID: 29898990
[No Abstract] [Full Text] [Related]
20. The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression.
Huang L; Malu S; McKenzie JA; Andrews MC; Talukder AH; Tieu T; Karpinets T; Haymaker C; Forget MA; Williams LJ; Wang Z; Mbofung RM; Wang ZQ; Davis RE; Lo RS; Wargo JA; Davies MA; Bernatchez C; Heffernan T; Amaria RN; Korkut A; Peng W; Roszik J; Lizée G; Woodman SE; Hwu P
Clin Cancer Res; 2018 Jul; 24(14):3366-3376. PubMed ID: 29496759
[No Abstract] [Full Text] [Related]
[Next] [New Search]
